Treatment of hair loss disorders with deuterated jak inhibitors

Patent metadata

Field	Value
Publication number	US-2020222408-A1
Application number	US-201916704402-A
Country	US
Kind code	A1
Filing date	Dec 5, 2019
Priority date	May 4, 2016
Publication date	Jul 16, 2020
Grant date	—

Abstract

or a pharmaceutically acceptable salt thereof. This invention also provides compositions comprising Compound (I) and the use of such compositions in the described methods.

First claim

1 - 31 . (canceled)

32 . A method of treating a hair loss disorder in a human subject, the method comprising administering to the human subject 16 mg/day of a compound represented by the following structural formula:

or a pharmaceutically acceptable salt thereof, wherein each position in Compound (I) designated specifically as deuterium has at least 95% incorporation of deuterium.

33 . The method of claim 32 , wherein the hair loss disorder is alopecia areata.

34 . The method of claim 32 , wherein the compound is administered orally.

35 . The method of claim 32 , wherein the compound is administered in a pharmaceutical formulation which is a tablet.

36 . The method of claim 32 , wherein the compound is administered once a day.

37 . The method of claim 32 , wherein the compound is administered twice a day.

38 . The method of claim 37 , wherein the step of administering comprises administering to the subject 8 mg twice per day.

39 . The method of claim 32 , wherein in Compound (I), any atom not designated as deuterium is present at its natural isotopic abundance.

40 . The method of claim 32 , wherein each position in Compound (I) designated specifically as deuterium has at least 97% incorporation of deuterium.

41 . A method of treating a hair loss disorder in a human subject, the method comprising administering to the human subject 24 mg/day of a compound represented by the following structural formula:

or a pharmaceutically acceptable salt thereof, wherein each position in Compound (I) designated specifically as deuterium has at least 95% incorporation of deuterium.

42 . The method of claim 41 , wherein the hair loss disorder is alopecia areata.

43 . The method of claim 41 , wherein the compound is administered orally.

44 . The method of claim 41 , wherein the compound is administered in a pharmaceutical formulation which is a tablet.

45 . The method of claim 41 , wherein the compound is administered once a day.

46 . The method of claim 41 , wherein the compound is administered twice a day.

47 . The method of claim 46 , wherein the step of administering comprises administering to the subject 12 mg twice per day.

48 . The method of claim 41 , wherein in Compound (I), any atom not designated as deuterium is present at its natural isotopic abundance.

49 . The method of claim 41 , wherein each position in Compound (I) designated specifically as deuterium has at least 97% incorporation of deuterium.

50 . A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and 8 mg of a compound represented by the following structural formula:

or a pharmaceutically acceptable salt thereof, wherein each position in Compound (I) designated specifically as deuterium has at least 95% incorporation of deuterium.

51 . A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and 12 mg of a compound represented by the following structural formula:

or a pharmaceutically acceptable salt thereof, wherein each position in Compound (I) designated specifically as deuterium has at least 95% incorporation of deuterium.

Assignees

• Concert Pharmaceuticals Inc

Inventors

• Wagner Amanda T
• Cassella James V
• Graham Philip B
• Braman Virginia
• Uttamsingh Vinita
• Von Hehn Jana
• Hamilton Colleen E

Classifications

• A61K9/20

  Pills, tablets, {discs, rods (A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095)} · CPC title

• A61K9/2054

  Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose · CPC title

• A61K9/0053

  Mouth and digestive tract, i.e. intraoral and peroral administration · CPC title

• A61K31/519 Primary

  ortho- or peri-condensed with heterocyclic rings · CPC title

• A61P17/14

  for baldness or alopecia · CPC title